Attgeno, a privately held clinical stage company devoted to development and commercialization of innovative and effective nitric oxide-donating drugs announces the appointment of Saurabh Mishra as its new Chief Financial Officer (CFO).
Saurabh Mishra brings over a decade of valuable experience in the healthcare and biotech industries. He currently serves as the Managing Partner at Farmantra, a corporate finance advisory firm specializing in providing strategic CFO and valuation services. With his financial acumen, honed through collaborations with numerous emerging biotech companies, Saurabh offers a compelling financial perspective to guide the strategic decisions made by the Board. His goal is to establish himself as a Value Integratorworking closely with the CEO to drive the long-term growth of the company. Saurabh has been advising numerous biotech CEOs in crafting strategic decisions, particularly in areas such as capital efficiency, capital allocation, scaling operations, and orchestrating successful exits to benefit shareholders.
“Saurabh brings a forward-looking mindset to Attgeno in his capacity as CFO, with his extensive leadership experience and profound strategic decision-making abilities, cultivated through his tenure with many different biotech companies. He is the perfect fit for Attgeno, especially as we expect to soon find ourselves at a critical value inflection point when we have received results for the currently ongoing phase-IIa study in patients with pulmonary hypertension in association with cardiac surgery.” says Per Agvald, CEO of Attgeno. “Saurabh is a seasoned expert in creating value for biotech companies, and his addition has further fortified our team as we continue to make strides in our clinical trials.”
“I’ve been following Attgeno since 2016 when I valued the lead candidate intrinsically and understood the risks and rewards of their assets. I’m genuinely impressed by the recent clinical progress achieved by Attgeno. I extend my gratitude to the Board and the entire team and eagerly anticipate collaborating to facilitate Attgeno’s growth by advancing Supernitro and exploring its potential applications in acute and chronic pulmonary hypertension.” says Saurabh Mishra.
Attgeno’s former CFO, Björn Westberg, has transitioned to a position on the Board of directors, replacing Elisabet Lindberg